Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Pharmacol.

Sec. Renal Pharmacology

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1683708

Development of a Venous Thromboembolism Risk Prediction Model for Patients with Primary Membranous Nephropathy Based on Machine LearningDevelopment of a Personalized VTE Risk Prediction Model for Patients with Primary Membranous Nephropathy Based on Machine Learning

Provisionally accepted
  • 1School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
  • 2Department of Pharmacy, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China
  • 3Department of Pharmacy, The Fourth People's Hospital of Chengdu, Chengdu, China
  • 4Department of Pharmacy, Chengdu Women and Children's Central Hospital, Chengdu, China

The final, formatted version of the article will be published soon.

Objective: This study utilizes real-world data from primary membranous nephropathy (PMN) patients to preliminarily develop a venous thromboembolism (VTE) risk prediction model with machine learning. The aim is to improve the rational use of prophylactic anticoagulant therapy by predicting VTE risk in these patients. Methods: We collected diagnostic and treatment data for PMN patients hospitalized at Sichuan Provincial People's Hospital from January 1, 2018, to September 30, 2024. The data was divided into training and test sets at an 8:2 ratio, followed by processed using combinations of three imputation methods, three sampling methods, and three feature selection methods. After preprocessing, fourteen machine learning algorithms were employed to develop a predictive model for VTE risk in PMN patients. The SHapley Additive exPlanation (SHAP) method was used to interpret the contribution of outcome features. Finally, a VTE risk prediction tool for PMN patients was constructed using Streamlit. Results: A total of 643 patients with PMN were included in the study, of whom 93 developed VTE. Among the 504 models constructed, the NGBoost model, which incorporated imputation by K-Nearest Neighborrandom forests, sampling by Borderline-SMOTE, and feature selection by Frequency-based Selection, was identified as the optimal model, achieving an area under the curve (AUC) of 0.911. The optimal model included ten features: D-dimer (DD), Fibrin Degradation Products (FDP)>5mg/L, international normalized ratio (INR) of prothrombin, Recurrent nephrotic syndrome (RNS), cholinesterase (CHE), Urinary Microalbumin to Creatinine Ratio (umALB/Ucr), statins, antithrombin III (AT III) activity, albumin, and anti-phospholipase A2 receptor antibody (aPLA2Rab). Finally, an online predictive tool based on the optimal model was developed to provide real-time individualized VTE risk predictions for PMN patients. Conclusion: This study developed a personalized risk prediction model for VTE in PMN patients using machine learning techniques. Additionally, a web-based tool for this predictive model was created. The model demonstrates strong predictive performance and can assist in clinical decision-making for the prevention and treatment of VTE in PMN patients.

Keywords: Primary membranous nephropathy, Venous Thromboembolism, Riskfactors, machine learning, Prediction model

Received: 21 Aug 2025; Accepted: 20 Oct 2025.

Copyright: © 2025 Lian, Wu, wang, Zheng, Han, Yin, Wu and Yuan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Qinan Yin, 522922633@qq.com
Xingwei Wu, wuxingwei@med.uestc.edu.cn
Bian Yuan, bianyuan567@126.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.